Executive Director RLT Strategy and Early Portfolio

AAA Statement :<br>Advanced Accelerator Applications, a Novartis company, is an innovative medicines company focused on the development of products for targeted radioligand therapy and precision radioligand imaging. We are committed to transforming patients’ lives by leading innovation in nuclear medicine.<br> AAA offers professionals the opportunity to face new challenges and pursue a career in a fast growing, technology driven healthcare company. We are passionate about improving patient health by leading innovation in nuclear medicine. We are looking for people who share our commitment to help us achieve this goal. Advanced Accelerator Applications is an Equal Opportunity Employer (EOE).<br>Job Description :<br>POSITION PURPOSE: <br><br>The Global RLT Strategy and Early Portfolio Executive Director will be accountable for providing strategic leadership for developing overall, cross-functional programs of a priority disease area, especially early in lifecycle – focused on shaping assets with strong commercial potential in line with TA priorities. The role provides provides strategic direction and functional expertise in a cross-functional RSC team and prioritizes US first with enhanced focus on major markets (e.g., China, Japan, Germany). Ensure close collaboration with Strategy and Early Product, , NIBR, GDD and MAP teams.<br><br>1. RSC strategy aligned with Therapeutic Area (TA) strategy<br>Collaborating to ensure definition and execution of a competitive strategy to establish Novartis as true industry leader within the RLT and maximize patient impact by influencing/ partnering across the disease ecosystem. <br>• Contribute to defining RLT aspirations, goals, and priorities or across the assets within the RLT, supporting strategic cross- RLT -brand alignments to continuously ensure speaking with one voice to the wider organization<br>• Support key stakeholders (Global RLT Head, TA Strategy & Early Portfolio Team, IM-US, IMI major markets, MAP team, NIBR & GDD) with early commercial evaluations of assets, particularly at development decision points, bringing deep RLT expertise and commercial acumen; in particular, supporting the assets not reaching Innovative Medicine’s strategy, enterprise value criteria or RLT strategy are closed out swiftly <br>• Contribute to the development of robust forecasts<br>• Define light-touch (RLT -specific) above-country Health Systems & Policy strategy (objectives, priorities)<br><br>2. Asset shaping <br>Shaping market-relevant assets to become Standard of Care with a focus on US<br>• Collaborate to develop transformative, US-centric Target Product Profiles (TPPs) that are tangible, provide a clear guidance to the GDD organization on what level of evidence is required. <br>• Make data-driven, decisive tradeoffs between needs of US and major markets (e.g., CN, JP, DE)<br>• Bring a deep understanding of customer needs and healthcare ecosystems in priority markets and innovative customer value management approaches to guide development programs<br>• Co-develop and execute integrated Evidence Plan (IEP) with input into GDD trial design - bringing a credible, aligned commercial perspective to maximize commercialization/patient access potential <br><br>3. Integrated early brand strategies<br>• Provide strategic leadership to ensure impactful, actionable early brand strategies until handover to International<br>• Co-develop Integrated Insights Plan, consolidating and aligning inputs and requirements across functions to achieve deep RLT ecosystem understanding (patient journey, competitive, access landscape, HCS budget impact and cost effectiveness analysis)<br>• Co-develop early Integrated Product Strategy (IPS) rooted in customer/ market centricity (until handover to International)<br>• Collaborate to define early medical affairs strategy as part IPS, incl. scientific platform/core claims, disease awareness, medical expert engagement, etc.<br>• Collaborate to ensure delivery of the early access, reimbursement, and pricing strategies (early Integrated Product Access Strategy) to shape value proposition for HCP / payer / patients / HCS <br>• Contribute to cross-functionally aligned stakeholder mapping/ prioritization and engagement plan<br><br>4. Brand management across the lifecycle <br>Accountable for maintaining the integrity, consistency, and evolution of each brand across the lifecycle <br>• Co-develop and maintain an impactful brand identity, positioning, aligning across commercial, medical requirements for global brand consistency<br>• Co-develop and maintain a pricing strategy framework/ link for global price cross-referencing <br>• Collectively define and coordinate lifecycle management (LCM) strategy (incl. indications strategy/ sequencing, formulations, connected devices, combinations, follow-on assets) <br><br>5. Collaboration <br>Successfully working within a cross-functional RLT team to achieve goals <br>• Work in a diverse, high performance, cross-functionally matrixed team including identifying and integrating expertise and inputs required from other teams to ensure successful delivery (e.g., MAP) <br>• Bring in functional expertise in cross-functional areas (commercial, medical, market access, development, finance) to ensure appropriate focus dedicated to assets<br>• Ensure appropriate compliance against company policies and procedures